Why the study?
Longer-term follow-up was needed to confirm whether early functional, quality of life, and right-heart reverse remodelling improvements after transcatheter tricuspid valve intervention are sustained.
Does transfemoral transcatheter tricuspid valve replacement improve tricuspid regurgitation and functional outcomes in patients with symptomatic ≥moderate tricuspid regurgitation?
Does transfemoral transcatheter tricuspid valve replacement improve tricuspid regurgitation and functional outcomes in patients with symptomatic ≥moderate tricuspid regurgitation?
Answers are grounded in this paper and cite their sources.
Transfemoral EVOQUE transcatheter tricuspid valve replacement provides sustained TR reduction and significant clinical and functional improvements at one year in a highly comorbid population.
BACKGROUND AND AIMS: For patients with symptomatic, severe tricuspid regurgitation (TR), early results of transcatheter tricuspid valve (TV) intervention studies have shown significant improvements in functional status and quality of life associated with right-heart reverse remodelling. Longer-term follow-up is needed to confirm sustained improvements in these outcomes. METHODS: The prospective, single-arm, multicentre TRISCEND study enrolled 176 patients to evaluate the safety and performance of transcatheter TV replacement in patients with ≥moderate, symptomatic TR despite medical therapy. Major adverse events, reduction in TR grade and haemodynamic outcomes by echocardiography, and clinical, functional, and quality-of-life parameters are reported to one year. RESULTS: Enrolled patients were 71.0% female, mean age 78.7 years, 88.0% ≥ severe TR, and 75.4% New York Heart Association classes III-IV. Tricuspid regurgitation was reduced to ≤mild in 97.6% (P < .001), with increases in stroke volume (10.5 ± 16.8 mL, P < .001) and cardiac output (0.6 ± 1.2 L/min, P < .001). New York Heart Association class I or II was achieved in 93.3% (P < .001), Kansas City Cardiomyopathy Questionnaire score increased by 25.7 points (P < .001), and six-minute walk distance increased by 56.2 m (P < .001). All-cause mortality was 9.1%, and 10.2% of patients were hospitalized for heart failure. CONCLUSIONS: In an elderly, highly comorbid population with ≥moderate TR, patients receiving transfemoral EVOQUE transcatheter TV replacement had sustained TR reduction, significant increases in stroke volume and cardiac output, and high survival and low hospitalization rates with improved clinical, functional, and quality-of-life outcomes to one year. Funded by Edwards Lifesciences, TRISCEND ClinicalTrials.gov number, NCT04221490.
No takes yet. Share an insight, caveat, or question.
Kodali et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: